Zealand Pharma CEO: Zegalogue launch continues as planned
The seminal launch of hypoglycemia medication Zegalogue has thus far gone according to plan, informs biotech group Zealand Pharma CEO Emmanuel Dulac, who declines to disclose figures for the development thus far, however.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL FRANK CHRISTENSEN
It's nearly two months back since last June when Zealand Pharma launched its hypoglycemia medication, Zegalogue, on the US market. According to the Danish biotechnology group's chief executive, Emmanuel Dulac, everything is going completely according to plan.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma sends blood sugar drug to US market
For subscribers
